166 related articles for article (PubMed ID: 19020542)
21. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
[TBL] [Abstract][Full Text] [Related]
22. Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells.
Veena P; Cornetta K; Davidson A; Agüero B; McMahel J; Traycoff CM; Srour EF
Bone Marrow Transplant; 1997 Jun; 19(12):1213-21. PubMed ID: 9208115
[TBL] [Abstract][Full Text] [Related]
23. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks.
Nowicki MO; Falinski R; Koptyra M; Slupianek A; Stoklosa T; Gloc E; Nieborowska-Skorska M; Blasiak J; Skorski T
Blood; 2004 Dec; 104(12):3746-53. PubMed ID: 15304390
[TBL] [Abstract][Full Text] [Related]
24. Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia.
Krämer A; Löffler H; Bergmann J; Hochhaus A; Hehlmann R
Leukemia; 2001 Jan; 15(1):62-8. PubMed ID: 11243401
[TBL] [Abstract][Full Text] [Related]
25. RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.
Yuan M; Wang Y; Qin M; Zhao X; Chen X; Li D; Miao Y; Otieno Odhiambo W; Liu H; Ma Y; Ji Y
Cancer Sci; 2021 Jul; 112(7):2679-2691. PubMed ID: 33949040
[TBL] [Abstract][Full Text] [Related]
26. Role of abnormal integrin-cytoskeletal interactions in impaired beta1 integrin function in chronic myelogenous leukemia hematopoietic progenitors.
Bhatia R; Munthe HA; Verfaillie CM
Exp Hematol; 1999 Sep; 27(9):1384-96. PubMed ID: 10480429
[TBL] [Abstract][Full Text] [Related]
27. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
Zhou LL; Zhao Y; Ringrose A; DeGeer D; Kennah E; Lin AE; Sheng G; Li XJ; Turhan A; Jiang X
J Exp Med; 2008 Oct; 205(11):2657-71. PubMed ID: 18936234
[TBL] [Abstract][Full Text] [Related]
28. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
29. Expression of p210 bcr/abl increases hematopoietic progenitor cell radiosensitivity.
Santucci MA; Anklesaria P; Laneuville P; Das IJ; Sakakeeny MA; FitzGerald TJ; Greenberger JS
Int J Radiat Oncol Biol Phys; 1993 Aug; 26(5):831-6. PubMed ID: 8344852
[TBL] [Abstract][Full Text] [Related]
30. BCR/ABL induces multiple abnormalities of cytoskeletal function.
Salgia R; Li JL; Ewaniuk DS; Pear W; Pisick E; Burky SA; Ernst T; Sattler M; Chen LB; Griffin JD
J Clin Invest; 1997 Jul; 100(1):46-57. PubMed ID: 9202056
[TBL] [Abstract][Full Text] [Related]
31. Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors.
Hiwase DK; White DL; Powell JA; Saunders VA; Zrim SA; Frede AK; Guthridge MA; Lopez AF; D'Andrea RJ; To LB; Melo JV; Kumar S; Hughes TP
Leukemia; 2010 Apr; 24(4):771-8. PubMed ID: 20130598
[TBL] [Abstract][Full Text] [Related]
32. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia.
Chu S; Li L; Singh H; Bhatia R
Cancer Res; 2007 Jul; 67(14):7045-53. PubMed ID: 17638918
[TBL] [Abstract][Full Text] [Related]
33. Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors.
Ramaraj P; Singh H; Niu N; Chu S; Holtz M; Yee JK; Bhatia R
Cancer Res; 2004 Aug; 64(15):5322-31. PubMed ID: 15289338
[TBL] [Abstract][Full Text] [Related]
34. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
[TBL] [Abstract][Full Text] [Related]
35. BCR/ABL-negative progenitors are enriched in the adherent fraction of CD34+ cells circulating in the blood of chronic phase chronic myeloid leukemia patients.
Grand FH; Marley SB; Chase A; Titley I; Healy L; Spencer A; Reiter A; Goldman JM; Gordon MY
Leukemia; 1997 Sep; 11(9):1486-92. PubMed ID: 9305602
[TBL] [Abstract][Full Text] [Related]
36. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
Drexler HG; MacLeod RA; Uphoff CC
Leuk Res; 1999 Mar; 23(3):207-15. PubMed ID: 10071072
[TBL] [Abstract][Full Text] [Related]
37. [Progress in laboratory medicine in chronic myeloid leukemia].
Miura A
Rinsho Byori; 1998 Dec; 46(12):1226-31. PubMed ID: 9916508
[TBL] [Abstract][Full Text] [Related]
38. Chronic myelogenous leukemia: molecular and cellular aspects.
Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
[TBL] [Abstract][Full Text] [Related]
39. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.
Verfaillie CM; Bhatia R; Miller W; Mortari F; Roy V; Burger S; McCullough J; Stieglbauer K; Dewald G; Heimfeld S; Miller JS; McGlave PB
Blood; 1996 Jun; 87(11):4770-9. PubMed ID: 8639848
[TBL] [Abstract][Full Text] [Related]
40. High Bcr-Abl expression prevents the translocation of Bax and Bad to the mitochondrion.
Keeshan K; Cotter TG; McKenna SL
Leukemia; 2002 Sep; 16(9):1725-34. PubMed ID: 12200687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
